The “4+7” quantity procurement is the second time that the Chinese government set up a new National Health Insurance Bureau in 2018, and the “4+7” quantity procurement means that the National Health Insurance Bureau uses medical insurance purchases. The main feature is the bidding for the products with large medical insurance. The characteristic is to uniformly purchase all the products that have passed the “BE evaluation”. The product of the lowest price wil get 70% market share of the products. For the drugs that have not been evaluated by “BE evaluation” , in 2 - 3 years, the company will gradually be withdrawed from the medical insurance market.
The following link is the article that has been selected for the second batch of the latest “4+7” volume procurement pilots, which can help Korean pharmaceutical companies to keep abreast of the latest changes in the Chinese pharmaceutical market.

https://weixin.sogou.com/link?url=dn9a_-gY295K0Rci_xozVXfdMkSQTLW6cwJThYulHEtVjXrGTiVgS2_893nAbZTSsjZCgsQWp1PdGziwfr3e0FqXa8Fplpd9aLtnkKMlYAhRk7bY0bI88O6zUIphCT6T1Bv3XhbFjbOqMhPpGpAODTX-U7V_ByiBefZgsg70xglhmRtmGwnofFLEvBi1WVgvIqimi5vmLPMxrQiVQ-0CQsrKf1aptCwJr3tXCAAzQ6dWmihchoSOPnuS1SGMQBxiu6HVYUTUoSDyPfCoem7FzA..&type=2&query=带量采购&k=18&h=j

If you are willing to learn more details, you can come to KHIDI for face-to-face communication.